CJC-1295 DAC vs No-DAC: Half-Life, Binding Kinetics, and Research Protocol Differences

Overview

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) developed to extend the half-life of endogenous GHRH (approximately 7 minutes) for research purposes. Two variants exist: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF 1-29). The structural difference, a lysine-maleimide conjugate in the DAC form, produces dramatically different pharmacokinetic profiles relevant to in vitro and in vivo research design.

The Drug Affinity Complex (DAC) Technology

DAC technology covalently links the peptide to circulating albumin in biological systems, dramatically extending half-life from approximately 30 minutes (CJC-1295 no-DAC) to 6–8 days (CJC-1295 DAC). The maleimide group in DAC reacts with the free thiol of Cys-34 on human serum albumin, creating a stable thioether bond that protects the peptide from enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and serum peptidases.

In cell-based assays, CJC-1295 DAC binds the GHRH receptor (GHRH-R) and stimulates cAMP accumulation in a dose-dependent manner. Binding affinity studies report Ki values in the low nanomolar range, comparable to native GHRH, with full agonist activity at pituitary somatotroph cell lines.

CJC-1295 No-DAC: Modified GRF 1-29

CJC-1295 no-DAC (Mod-GRF 1-29) retains the GHRH-R binding sequence but lacks the albumin-binding DAC moiety. Its half-life in biological systems is approximately 30 minutes, producing pulsatile rather than sustained GHRH receptor stimulation. This pulsatile profile is considered by some researchers to more closely mimic endogenous GHRH physiology.

The no-DAC form is susceptible to DPP-4 cleavage at the Ala-Glu bond at positions 2–3, though substitution of amino acids at positions 2, 8, 15, and 27 in Mod-GRF 1-29 (compared to native GHRH 1-29) increases enzymatic stability relative to native GHRH while retaining full receptor agonism.

Key Pharmacokinetic Comparison

Receptor Selectivity and Downstream Signalling

Both forms bind GHRH-R with high selectivity. Activation triggers Gs protein coupling, adenylyl cyclase stimulation, and elevated intracellular cAMP, which in turn activates protein kinase A (PKA) and downstream CREB phosphorylation, the canonical pathway for GH gene transcription and secretion in somatotroph cells.

In cell culture models, both analogues produce similar maximum cAMP responses (Emax), differing primarily in the temporal profile of receptor occupancy. Long-duration receptor activation by DAC forms raises questions around receptor desensitisation and downregulation in extended research paradigms.

Research Design Considerations

Selection between DAC and no-DAC variants depends on the research objective. For studies modelling sustained GHRH elevation, CJC-1295 DAC provides a pharmacokinetically stable background. For studies examining pulsatile GH secretion kinetics, or where tightly controlled on/off receptor modulation is required, the no-DAC form offers greater temporal control.

When used in combination with GHRPs such as ipamorelin or GHRP-6, the no-DAC form is commonly employed to synchronise GHRH and GHRP pulses, mimicking the natural synergistic co-secretion pattern observed physiologically.

Stability and Storage

Lyophilised CJC-1295 (both forms) is stable at room temperature for short periods but should be stored at -20°C for long-term retention of biological activity. Reconstituted solutions should be refrigerated at 2–8°C and used within 28 days. The DAC form is generally considered marginally more stable post-reconstitution due to its albumin-binding properties, though this advantage is irrelevant in cell-free assay systems.

For research use only. Not for human consumption. All Stackpure peptides carry a third-party COA confirming ≥99% purity by HPLC.